Video

Dr. Cohen on the Safety Profile of Cilta-Cel in Multiple Myeloma

Adam D. Cohen, MD, discusses the safety profile of ciltacabtagene autoleucel in patients with multiple myeloma, based on data from the phase 2 CARTITUDE-2 study.

Adam D. Cohen, MD, assistant professor of medicine, director, Myeloma Immunotherapy, University of Pennsylvania, discusses the safety profile of ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma, based on data from the phase 2 CARTITUDE-2 study (NCT04133636). 

The main hematologic toxicities observed with cilta-cel on the study were similar to those reported in the phase 1/2 CARTITUDE-1 trial (NCT03548207); they included neutropenia, anemia, and thrombocytopenia, according to Cohen. These toxicities are most often associated with lymphodepletion conditioning therapy, as well as the CAR T-cell therapy itself, Cohen explains.

The rates of grade 3/4 thrombocytopenia and anemia appeared to be less than what was reported on CARTITUDE-1, and prolonged grade 3/4 cytopenias also occurred less frequently; this may be because the CARTITUDE-2 study enrolled a less heavily pretreated population, Cohen concludes.

Related Videos
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Sundar Jagannath, MBBS
Kevin Kalinsky, MD, MS,
Aaron Gerds, MD
Paolo Tarantino, MD
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Shella Saint Fleur-Lominy, MD, PhD
Benjamin Levy, MD
Nader Sanai, MD, chief, Neurosurgical Oncology, director, Ivy Brain Tumor Center, Barrow Neurological Institute